246 related articles for article (PubMed ID: 21197471)
21. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
22. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
23. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
24. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E
Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900
[TBL] [Abstract][Full Text] [Related]
25. The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
Parrish JK; McCann TS; Sechler M; Sobral LM; Ren W; Jones KL; Tan AC; Jedlicka P
Oncotarget; 2018 Sep; 9(69):33110-33123. PubMed ID: 30237855
[TBL] [Abstract][Full Text] [Related]
26. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
Stolte B; Iniguez AB; Dharia NV; Robichaud AL; Conway AS; Morgan AM; Alexe G; Schauer NJ; Liu X; Bird GH; Tsherniak A; Vazquez F; Buhrlage SJ; Walensky LD; Stegmaier K
J Exp Med; 2018 Aug; 215(8):2137-2155. PubMed ID: 30045945
[TBL] [Abstract][Full Text] [Related]
27. The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view.
Zhang Y; Song J; Shi Q; Song X; Shen L; Zhou J; Shao J
Jpn J Clin Oncol; 2019 Jul; 49(7):604-613. PubMed ID: 30927420
[TBL] [Abstract][Full Text] [Related]
28. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.
Pishas KI; Adwal A; Neuhaus SJ; Clayer MT; Farshid G; Staudacher AH; Callen DF
Sci Rep; 2015 Jun; 5():11465. PubMed ID: 26095524
[TBL] [Abstract][Full Text] [Related]
29. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
30. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
[TBL] [Abstract][Full Text] [Related]
31. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription.
Navarro D; Agra N; Pestaña A; Alonso J; González-Sancho JM
Carcinogenesis; 2010 Mar; 31(3):394-401. PubMed ID: 20019092
[TBL] [Abstract][Full Text] [Related]
32. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.
Wadayama B; Toguchida J; Yamaguchi T; Sasaki MS; Yamamuro T
Br J Cancer; 1993 Dec; 68(6):1134-9. PubMed ID: 8260365
[TBL] [Abstract][Full Text] [Related]
33. The Promoter-Associated Noncoding RNA
Palombo R; Frisone P; Fidaleo M; Mercatelli N; Sette C; Paronetto MP
Cancer Res; 2019 Jul; 79(14):3570-3582. PubMed ID: 31072811
[TBL] [Abstract][Full Text] [Related]
34. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
Niemeyer BF; Parrish JK; Spoelstra NS; Joyal T; Richer JK; Jedlicka P
PLoS One; 2015; 10(1):e0116895. PubMed ID: 25603314
[TBL] [Abstract][Full Text] [Related]
35. Anatomic Origin of Osteochondrogenic Progenitors Impacts Sensitivity to EWS-FLI1-Induced Transformation.
Pfaltzgraff ER; Apfelbaum A; Kassa AP; Song JY; Jiang W; Suhan TK; Wellik DM; Lawlor ER
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30845695
[TBL] [Abstract][Full Text] [Related]
36. Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-
Xia Y; Wang L; Ma X; Li X
Hum Gene Ther; 2020 Aug; 31(15-16):881-890. PubMed ID: 32013587
[TBL] [Abstract][Full Text] [Related]
37. EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
Cidre-Aranaz F; Alonso J
Front Oncol; 2015; 5():162. PubMed ID: 26258070
[TBL] [Abstract][Full Text] [Related]
38. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
39. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.
Pérot G; Chibon F; Montero A; Lagarde P; de Thé H; Terrier P; Guillou L; Ranchère D; Coindre JM; Aurias A
Am J Pathol; 2010 Oct; 177(4):2080-90. PubMed ID: 20884963
[TBL] [Abstract][Full Text] [Related]
40. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth.
Carrillo J; García-Aragoncillo E; Azorín D; Agra N; Sastre A; González-Mediero I; García-Miguel P; Pestaña A; Gallego S; Segura D; Alonso J
Clin Cancer Res; 2007 Apr; 13(8):2429-40. PubMed ID: 17438102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]